Both finalists in the second annual BioCrossroads New Venture Competition’s “Pre-Venture” category have ties to the IU Research and Technology Corp.
Both Emphymab Biotech, a firm developing a first disease-modifying platform drug for emphysema and other chronic diseases; and Rene Medical, which is developing a system to treat contrast induced nephropathy, are up for the $10,000 prize.
In addition, both ventures are part of IURTC’s Spin-Up program, which provides valuable early-stage technology commercialization support to IU-affiliated companies.
The annual BioCrossroads competition also awards three cash prizes to life sciences and health information technology companies with Hoosier ties and a high potential for attracting investment capital.
Winners will be announced at the Indiana Life Sciences Summit Networking Reception on Monday. Full details of all the finalists are available online.